I am a physical chemist with expertise in the field of colloidal science, skilled in experiments, theory and simulations to solve pharmaceutical problems – from small molecules to macromolecules like mRNA.
I have been working at AstraZeneca for over 25 years on gastrointestinal absorption, oral vaccines, molecular simulations, nanoparticle systems of poorly soluble drugs and more recently, on lipid nanoparticles and exosomes incorporating nucleic acids.
I received my PhD at Chalmers University of Technology in 1993. In 2007, I became an adjunct Professor at the Department of Chemistry and Molecular Biology, University of Gothenburg, which enhances my interaction with the academic community.
Succeeded in incorporating exogeneous functional mRNA molecules into exosomes, our own biological delivery vehicle
Discovered the internal structure of mRNA-containing lipid nanoparticles and how their surface could be tailored to optimize their biological function
Invented a principle to minimize unwanted side effects for mRNA-containing lipid nanoparticles
Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation.
Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Arteta MY, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvistc AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Proceedings of the National Academy of Sciences (2018), 115: E3351. Publication link.
Nanocrystal formulations of a poorly soluble drug. 1. In vitro characterization of stability, stabilizer adsorption and uptake in liver cells.
Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice.
Sigfridsson K, Skantze P, Skantze U, Svensson L, Löfgren L, Nordell P, Michaelsson E, Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. International Journal of Pharmaceutics (2017), 524: 248. Publication link.